Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
130,300
+3,700 (2.92%)
At close: Feb 27, 2026
Market Cap2.77T
Revenue (ttm)25.48M -100.0%
Net Income-36.88B
EPS-2,048.17
Shares Out21.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume632,243
Average Volume332,485
Open124,600
Previous Close126,600
Day's Range123,900 - 132,800
52-Week Range15,950 - 146,600
Betan/a
RSI58.77
Earnings DateMar 20, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements